Five Prime Therapeutics (FPRX) Tops Q3 EPS by 6c

Five Prime Therapeutics (NASDAQ: FPRX) reported Q3 EPS of ($0.93), $0.06 better than the analyst estimate of ($0.99). Revenue for the quarter came in at $200 thousand versus the consensus estimate of $4.9 million.

For earnings history and earnings-related data on Five Prime Therapeutics (FPRX) click here.

You May Also Be Interested In

• EU proposes to curb Airbnb and short-term rentals amid housing shortage
• Goldman Sachs Downgrades Schindler Holding AG (SCHN:SW) (SHLAF) to Sell
• Dell’s earning report was bullish for Intel CPU demand, analyst says